Soft Tissue Sarcoma and Rare Connective Tissue Tumours
The Italian Sarcoma Group focuses on advanced and metastatic sarcoma subtypes, with particular attention to solitary fibrous tumour, leiomyosarcoma, mesenchymal chondrosarcoma, and desmoplastic small round cell tumor. Its research activity is centered on difficult-to-treat disease settings in adults and young adults requiring systemic treatment beyond first-line care.
- Advanced solitary fibrous tumour
- Metastatic leiomyosarcoma
- Mesenchymal chondrosarcoma
- Desmoplastic small round cell tumor
These studies address progressive locally advanced and metastatic disease, reflecting a strong therapeutic interest in rare soft tissue sarcoma entities with limited treatment options.
Systemic Therapy in Pre-treated Disease
The sponsor’s clinical research examines systemic treatment strategies for patients previously exposed to anthracycline-based chemotherapy, with interest in later-line therapy for advanced sarcoma. The funded trials include agents used after prior treatment failure and in relapsed disease.
- Trabectedin
- Eribulin
- Lurbinectedin
- Irinotecan
This area highlights a therapeutic emphasis on second-line to fourth-line treatment for patients with advanced sarcoma subtypes.
Molecularly Defined Sarcoma
Research activity includes tumours defined by specific molecular alterations, such as HEY1-NCOA2-positive mesenchymal chondrosarcoma and EWSR1-WT1 translocated desmoplastic small round cell tumor. The sponsor’s portfolio reflects interest in histologically rare cancers with distinct molecular profiles.
- HEY1-NCOA2-positive disease
- EWSR1-WT1 translocation
- Progressive locally advanced disease
- Metastatic disease
These therapeutic areas support clinical evaluation in biologically defined sarcoma populations where molecular characterisation is central to treatment selection.
Comparative Activity in Advanced Sarcoma
The sponsored studies also examine comparative treatment activity in metastatic or locally advanced leiomyosarcoma, alongside observational assessment of therapy performance in routine clinical settings. The research interest extends to evaluating established cytotoxic and sarcoma-directed agents in relapsed disease.
- Comparative treatment activity
- Locally advanced leiomyosarcoma
- Metastatic relapse
- Therapy after conventional chemotherapy
Its trial portfolio is concentrated in advanced sarcoma care, with active research sites across multiple countries and a consistent focus on rare oncologic conditions.
